Australian industry demands clarity on IVD (in vitro diagnostic) classification
This article was originally published in Clinica
As the date for the trans Tasman regulatory agency launch draws ever closer, Australian in vitro diagnostics (IVD) manufacturers confess to still being somewhat in the dark about grouping and the associated application fee structure.
You may also be interested in...
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.